In Vivo/In Vitro: Plac 1 Vaccine for Breast Cancer Prevention

Weill Medical Coll Of Cornell Univ, New York NY

Investigators

Abstract

The Contractor shall develop and optimize PLAC1 with or without IL12 in either/or DNA-based plasmid or replication deficient virus like recombinant vaccinia vectors. Vaccines in these two diverse delivery vectors should be tested in a head-to-head comparison for efficacy in two GEM models, MMTV-PPARand BRCA1ex11/p53+/- mice.